Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16075245 | 0.89 | BTK (0.37) | BTKEGFRCDK2CDK7CDK9 | |
| SCHEMBL16127676 | 0.83 | BTK (0.38) | BTKEGFRJAK3 | |
| SCHEMBL16075276 | 0.80 | CDK2 (0.36) | BTKEGFRCDK2CDK7CDK9 | |
| SCHEMBL16074970 | 0.80 | BTK (0.41) | BTKCDK2CDK7CDK9JAK3 | |
| SCHEMBL16078786 | 0.79 | BTK (0.37) | BTKEGFRJAK3 | |
| SCHEMBL16075243 | 0.78 | CRHBP (0.31) | — | |
| SCHEMBL16122877 | 0.78 | BTK (0.43) | BTKCDK2CDK7CDK9JAK3 | |
| SCHEMBL19909705 | 0.75 | BTK (0.38) | BTKJAK3 | |
| SCHEMBL16075017 | 0.74 | BTK (0.41) | BTKEGFRCDK7CDK9JAK3 | |
| SCHEMBL16075006 | 0.74 | BTK (0.44) | BTKCDK2CDK7CDK9JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895750-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20140275012-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275012-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885EGFR 307/4885CDK2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.